Introduction Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third-
leading cause of cancer-related mortality in the world. Areas covered This review will …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the third
leading cause of cancer-related death worldwide. Single-agent anti-PD-1 immune …

PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–
associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand …

We employed scRNA sequencing to extensively characterize the cellular landscape of
human liver from development to disease. Analysis of∼ 212,000 cells representing human …

PURPOSE Donafenib, a novel multikinase inhibitor and a deuterated sorafenib derivative,
has shown efficacy in phase Ia and Ib hepatocellular carcinoma (HCC) studies. This study …

The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Objective This trial compared the efficacy and safety of transarterial chemoembolisation
(TACE) plus sorafenib with TACE alone using a newly established TACE-specific endpoint …

The Liver Imaging Reporting and Data System (LI-RADS) is composed of four individual
algorithms intended to standardize the lexicon, as well as reporting and care, in patients with …

Transarterial chemoembolization (TACE) is a standard treatment for intermediate-stage
hepatocellular carcinoma (HCC). In this review, we summarize recent updates on the use of …

This guidance provides a data-supported approach to the diagnosis, staging, and treatment
of patients diagnosed with hepatocellular carcinoma (HCC). A guidance document is …